- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04413201
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Anne Ehrlich, Dr med
- Phone Number: 9945 +49 6131 17
- Email: ehrich@izks-mainz.de
Study Contact Backup
- Name: Thomas Wehler, Prof Dr. med.
- Phone Number: 58544 +49 641985
- Email: thomas.wehler@innere.med.uni-giessen.de
Study Locations
-
-
-
Berlin, Germany, 13125
- Evangelische Lungenklinik Berlin
-
Bremen, Germany, 28325
- Klinikum Bremen-Ost
-
Hamburg, Germany, 20251
- Studiengesellschaft Hämato-Onkologie Hamburg
-
Hamm, Germany, 59063
- Evangelisches Krankenhaus Hamm
-
Immenstadt, Germany, 87509
- Klinikverbund Allgäug gGmbH, Klinik für Pneumologie, c/o Klinik
-
Konstanz, Germany, 78464
- Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz Mbh
-
Löwenstein, Germany, 74245
- Klinik Löwenstein gGmbH
-
Regensburg, Germany, 93053
- Universitätsklinikum Regensburg
-
-
Bayern
-
München, Bayern, Germany, 80336
- Klinikum der Ludwig-Maximilians-Universität München
-
-
Hessen
-
Gießen, Hessen, Germany, 35392
- Universitätsklinikum Gießen Marburg
-
Offenbach, Hessen, Germany, 63069
- Sana-Klinikum Offenbach
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed non-squamous NSCLC harboring EGFR mutation positive but T790M mutation negative by local testing
- Unresectable stage UICC ≥ IIIb or metastatic stage UICC IV disease
- TKI naïve for metastatic NSCLC, neoadjuvant or adjuvant chemotherapy allowed
- At least one evaluable lesion according to RECIST v1.1
- Age ≥ 18 years
- ECOG performance status 0 - 2
Adequate organ function, defined as all of the following:
- Absolute neutrophil count (ANC) ≥ 1500/mm3. (ANC > 1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the coordinating investigator)
- Platelet count ≥ 75,000/mm3
- Estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m2 according to the Cockcroft-Gault formula d. If history of cardiac comorbidity: Left ventricular function with resting ejection fraction ≥ 50% or above the institutional lower limit of normal (LLN)
e. Total Bilirubin ≤ 1.5 times upper limit of normal (ULN), (if related to liver metastases ≤ 3 times ULN). (Patients with Gilbert's syndrome total Bilirubin must be ≤ 4 times institutional upper limit of normal) f. Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 times the upper limit of normal (ULN) (if related to liver metastases ≤ 5 times ULN)
- Recovered from any previous therapy related toxicity to ≤ Grade 1 at before randomization (except for stable sensory neuropathy ≤ Grade 2 and alopecia)
- Written informed consen
Exclusion Criteria:
- Any investigational drug within 30 days or hormonal anticancer treatment within 2 weeks prior to randomization (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)
- T790M mutation positive tumors (by local testing)
Radiotherapy within 2 weeks prior to randomization, except as follows:
- Palliative radiation to target organs other than chest may be allowed up to 1 week prior to randomization
- Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with coordinating investigator prior to enrolling
- Major surgery within 2 weeks before starting study treatment or scheduled for surgery during the projected course of the study
- Known hypersensitivity to afatinib or osimertinib or the excipients of any of the trial drugs
History or presence of clinically relevant cardiovascular abnormalities such as
- uncontrolled hypertension
- congestive heart failure NYHA classification of ≥ 3
- unstable angina or poorly controlled arrhythmia as determined by the investigator
- Myocardial infarction within 6 months prior to randomization
- Clinically important abnormalities in rhythm and conduction as measured by resting electrocardiogram (ECG) (e.g. QTc interval greater than 470 ms) or QTc interval prolongation with signs/symptoms of serious arrhythmia
- Congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or intake of medicinal products that are known to prolong the QTc interval
Patients with a past or present medical history of
- Interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD
- Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
- Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhoea, malabsorption)
- Known active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier
- Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured
Pregnancy and contraception:
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at informed consent, for the duration of study participation and for at least 2 months for females and 4 months for males after last dose
- Requiring treatment with any of the prohibited concomitant medications protein Inhibitors/Inductors CYP3A4/5 Inhibitors/Inductors that cannot be stopped for the duration of trial participation or concomitant St. John's Wort
- Uncontrolled brain metastases (Patients with brain or subdural metastases are not eligible, unless they have completed local therapy (≤ 2 weeks apart from last radiotherapy or radiosurgery) and have discontinued the use of corticosteroids, anticonvulsants or have been on stable dose of corticosteroids (i.e. Dexamethasone ≤ 8 mg) for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment) or Leptomeningeal carcinomatosis 11. Other contraindications to study treatment (Investigators opinion) or legal incapacity or limited legal capacity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Afatinib
Afatinib followed by osimertinib or ICT depending on T790M status
|
Afatinib followed by osimertinib or ICT
Other Names:
Osimertinib followed by ICT
|
Active Comparator: Osimertinib
Osimertinib followed by ICT
|
Osimertinib followed by ICT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to EGFR-TKI failure within 24 months for afatinib followed by osimertinib in T790Mpositive group vs osimertinib
Time Frame: 24 months
|
The main objective is to investigate whether the time to EGFR-TKI failure at 24 months is better for the treatment sequence of afatinib followed by osimertinib in the T790M positive group compared to osimertinib.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to EGFR-TKI failure (afatinib versus osimertinib)
Time Frame: 24 months
|
Time from randomization until ICT is indicated
|
24 months
|
Progression-free survival (PFS: afatinib followed by osimertinib or ICT vs osimertinib followed by ICT)
Time Frame: 24 months
|
Time from randomization until disease progression according to RECIST or death
|
24 months
|
Overall Survival (OS)
Time Frame: 24 months
|
Survival Status
|
24 months
|
Response Rate (RR)
Time Frame: 12 months
|
CR+PR according to RECIST
|
12 months
|
Response Rate (RR)
Time Frame: 24 months
|
CR+PR according to RECIST
|
24 months
|
Disease Control Rate (DCR)
Time Frame: 12 months
|
CR+PR+SD according to RECIST
|
12 months
|
Disease Control Rate (DCR)
Time Frame: 24 months
|
CR+PR+SD according to RECIST
|
24 months
|
Adverse Events
Time Frame: 24 months
|
Adverse Events as assessed by intensity of the of the adverse events and the causal relation to trial medication Intensity/Severity: investigator will use the following definitions of severity in accordance with National Cancer Institute common terminology criteria for adverse events, CTCAE, version 5.0; assessment of the relationship of an adverse event to the administration of study drug is a clinical decision by the investigator Institute common terminology criteria for adverse events, CTCAE, version 5.0
|
24 months
|
Symptom control assessed by patient-reported quality of life (QoL): EQ-5D
Time Frame: 24 months
|
patient-reported quality of life assessed by European Quality of Life 5 Dimensions Questionnaire (EQ-5D)
|
24 months
|
Symptom control assessed by patient-reported quality of life (QoL): EORTC QLQ-C30
Time Frame: 24 months
|
patient-reported quality of life assessed by Questionnaire of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
|
24 months
|
Symptom control assessed by patient-reported quality of life (QoL): EORTC QLQ-LC29
Time Frame: 24 months
|
EORTC QLQ-LC29
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas Wehler, Prof Dr med, Universitätsklinikum Gießen Marburg
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Osimertinib
- Afatinib
Other Study ID Numbers
- AFAMOSI
- 2019-002197-31 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-squamous NSCLC
-
Jair Bar, M.D., Ph.D.Not yet recruiting
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
First Affiliated Hospital Xi'an Jiaotong UniversityTang-Du Hospital; Yan'an University Affiliated HospitalUnknownNon-squamous NSCLCChina
-
Jiangsu Cancer Institute & HospitalNot yet recruiting
-
Shanghai Chest HospitalMerck Sharp & Dohme LLCRecruitingNon-squamous NSCLCChina
-
PfizerTerminatedAdvanced Non-squamous NSCLCChina
-
LanZhou UniversityGeneral Hospital of Ningxia Medical UniversityUnknown
-
Hunan Province Tumor HospitalCompletedNon-squamous NSCLCChina
-
Guangdong Association of Clinical TrialsUnknownAdvanced Non-squamous NSCLCChina
-
AmgenTerminatedAdvanced Non-squamous NSCLC
Clinical Trials on Afatinib
-
Boehringer IngelheimCompleted
-
Centre Leon BerardBoehringer IngelheimCompletedHead and Neck Squamous Cell CarcinomaFrance
-
University of ChicagoNational Cancer Institute (NCI)RecruitingRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral CancerUnited States
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungGreece
-
Boehringer IngelheimCompletedNeuroectodermal Tumors | RhabdomyosarcomaUnited States, Spain, Canada, Germany, Italy, United Kingdom, Australia, Austria, Denmark, Faroe Islands, France, Netherlands
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimApproved for marketing
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimNo longer available
-
University College, LondonBoehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungUnited Kingdom